The role of radiation therapy in the management of non-functioning pituitary adenomas
Tóm tắt
Surgical removal of non-functioning pituitary adenoma (NFPA) is the first-choice therapeutic option, but radical removal of the tumor cannot be accomplished in all patients. The best strategy to prevent regrowth of NFPA is still a matter of debate. Adjuvant radiotherapy is very effective in reducing recurrence rate after incomplete removal of NFPA, but concerns still exist about long-term toxicity of radiation. Different modalities have been developed to irradiate the pituitary region. One major distinction is between radiation techniques that deliver the total dose in multiple sessions using 3 fixed radiation beams and radio-surgical equipment that delivers the total dose to the target volume in a single treatment session. Progression-free survival of patients with NFPA treated by adjuvant radiotherapy is well above 90% at 5 yr in most studies and diminishes only slightly at 10 yr. Very few studies have a more prolonged follow-up. In comparison, the 5- and 10-yr estimated recurrence rate without adjuvant radiotherapy ranged from 15% to 51% and from 44% to 78%, respectively. Complications of radiation include rare but severe side-effects, such as secondary brain neoplasm, optic neuropathy, cerebrovascular accidents, and more frequent but less severe complications, such as pituitary deficiency. Optimal management of patients with residual or recurring NFPA after surgical debulking can be achieved through the judicious use of different treatment options, necessitating close cooperation between neurosurgeons, endocrinologists, and radiation oncologists.
Tài liệu tham khảo
Saeger W, Lüdecke DK, Buchfelder M, Fahlbusch R, Quabbe HJ, Petersenn S. Pathohistological classification of pituitary tumors: 10 years of experience with the German Pituitary tumor Registry. Eur J Endocrinol 2007, 156: 203–16.
Black PM, Hsu DW, Klibanski A, et al. Hormone production in clinically nonfunctioning pituitary adenomas. J Neurosurg 1987, 66: 244–50.
Snyder PJ. Gonadotroph cell adenomas of the pituitary. Endocrinol Rev 1985, 6: 552–63.
Yamada S, Ohyama K, Taguchi M, et al. A study of the correlation between morphological findings and biological activities in clinically nonfunctioning pituitary adenomas. Neurosurgery 2007, 61: 580–4; discussion 584–5.
Asa SL. The pathology of pituitary tumors. Endocrinol Metab Clin North Am 1999, 28: 13–43.
Losa M, Mortini P, Barzaghi R, Franzin A, Giovanelli M. Endocrine inactive and gonadotroph adenomas: diagnosis and management. J Neurooncol 2001, 54: 167–77.
Dekkers OM, Pereira AM, Romijn JA. Treatment and follow-up of clinically nonfunctioning pituitary macroadenomas. J Clin Endocrinol Metab 2008, 93: 3717–26.
Woollons AC, Hunn MK, Rajapakse YR, et al. Non-functioning pituitary adenomas: indications for postoperative radiotherapy. Clin Endocrinol (Oxf) 2000, 53: 713–7.
Soto-Ares G, Cortet-Rudelli C, Assaker R, et al. MRI protocol technique in the optimal therapeutic strategy of non-functioning pituitary adenomas. Eur J Endocrinol 2002, 146: 179–86.
Boelaert K, Gittoes NJL Radiotherapy for non-functioning pituitary adenomas. Eur J Endocrinol 2001, 144: 569–75.
Losa M, Mortini P, Barzaghi R, et al. Early results of surgery in patients with nonfunctioning pituitary adenoma and analysis of the risk of tumor recurrence. J Neurosurg 2008, 108: 525–32.
Gittoes NJ. Radiotherapy for non-functioning pituitary tumors — when and under what circumstances? Pituitary 2003, 6: 103–8.
Pirzkall A, Debus J, Haering P, et al. Intensity modulated radiotherapy (IMRT) for recurrent, residual, or untreated skull-base meningiomas: preliminary clinical experience. Int J Radiat Oncol Biol Phys 2003, 55: 362–72.
Mackley HB, Reddy CA, Lee SY, et al. Intensity-modulated radiotherapy for pituitary adenomas: the preliminary report of the Cleveland Clinic experience. Int J Radiat Oncol Biol Phys 2007, 67: 232–9.
Yartsev S, Kron T, Cozzi L, Fogliata A, Bauman G. Tomotherapy planning of small brain tumours. Radiother Oncol 2005, 74: 49–52.
Fogliata A, Clivio A, Nicolini G, Vanetti E, Cozzi L. Intensity modulation with photons for benign intracranial tumours: a planning comparison of volumetric single arc, helical arc and fixed gantry techniques. Radiother Oncol 2008, 89: 254–62.
Marks LB. Conventional fractionated radiation therapy vs. radio-surgery for selected benign intracranial lesions (arteriovenous malformations, pituitary adenomas, and acoustic neuromas). J Neurooncol 1993, 17: 223–30.
Sanno N, Oyama K, Tahara S, Teramoto A, Kato Y. A survey of pituitary incidentaloma in Japan. Eur J Endocrinol 2003, 149: 123–7.
Molitch ME. Nonfunctioning pituitary tumors and pituitary incidentalomas. Endocrinol Metab Clin North Am 2008, 37: 151–71.
Arita K, Tominaga A, Sugiyama K, et al. Natural course of incidentally found nonfunctioning pituitary adenoma, with special reference to pituitary apoplexy during follow-up examination. J Neurosurg 2006, 104: 884–91.
Dekkers OM, Hammer S, de Keizer RJ, et al. The natural course of non-functioning pituitary macroadenomas. EurJ Endocrinol 2007, 156: 217–24.
Karavitaki N, Collison K, Halliday J, et al. What is the natural history of nonoperated nonfunctioning pituitary adenomas? Clin Endocrinol (Oxf) 2007, 67: 938–43.
Gittoes NJ, Bates AS, Tse W, et al. Radiotherapy for non-function pituitary tumours. Clin Endocrinol (Oxf) 1998, 48: 331–7.
Turner HE, Stratton IM, Byrne JV, Adams CBT, Wass JA. Audit of selected patients with nonfunctioning pituitary adenomas treated without irradiation — a follow-up study. Clin Endocrinol (Oxf) 1999, 51: 281–4.
Greenman Y, Ouaknine G, Veshchev I, Reider-Groswasser II, Segev Y, Stern N. Postoperative surveillance of clinically nonfunctioning pituitary macroadenomas: markers of tumor quiescence and regrowth. Clin Endocrinol (Oxf) 2003, 58: 763–9.
Ferrante E, Ferraroni M, Castrignanò T, et al. Non-functioning pituitary adenoma database: a useful resource to improve the clinical management of pituitary tumors. Eur J Endocrinol 2006, 155: 823–9.
Park P, Chandler WF, Barkan AL, et al. The role of radiation therapy after surgical resection of nonfunctional pituitary macroadenomas. Neurosurgery 2004, 55: 100–6; discussion 106–7.
van den Bergh AC, van den Bergh G, Schoorl MA, et al. Immediate postoperative radiotherapy in residual nonfunctioning pituitary adenoma: beneficial effect on local control without additional negative impact on pituitary function and life expectancy. Int J Radiat Oncol Biol Phys 2007, 67: 863–9.
Brochier S, Galland F, Kujas M, et al. Factors predicting relapse of nonfunctioning pituitary macroadenomas after neurosurgery: a study of 142 patients. Eur J Endocrinol 2010, 163: 193–200.
Dekkers OM, Pereira AM, Roelfsema F, et al. Observation alone after transsphenoidal surgery for nonfunctioning pituitary macroadenoma. J Clin Endocrinol Metab 2006, 91: 1796–801.
O’Sullivan EP, Woods C, Glynn N, et al. The natural history of surgically treated but radiotherapy- naïve nonfunctioning pituitary adenomas. Clin Endocrinol (Oxf) 2009, 71: 709–14.
Lillehei KO, Kirschman DL, Kleinschmidt-DeMasters BK, Ridgway EC. Reassessment of the role of radiation therapy in the treatment of endocrine-inactive pituitary macroadenomas. Neurosurgery 1998, 43: 432–8; discussion 438–9.
Alameda C, Lucas T, Pineda E, et al. Experience in management of 51 non-functioning pituitary adenomas: indications for post-operative radiotherapy. J Endocrinol Invest 2005, 28: 18–22.
Chang EF, Zada G, Kim S, et al. Long-term recurrence and mortality after surgery and adjuvant radiotherapy for nonfunctional pituitary adenomas. J Neurosurg 2008, 108: 736–45.
Scheithauer BW, Jaap AJ, Horvath E, et al. Clinically silent corticotroph tumors of the pituitary gland. Neurosurgery 2000, 47: 723–9; discussion 729–30.
Webb KM, Laurent JJ, Okonkwo DO, Lopes MB, Vance ML, Laws ER Jr. Clinical characteristics of silent corticotrophic adenomas and creation of an internet-accessible database to facilitate their multi-institutional study. Neurosurgery 2003, 53: 1076–84; discussion 1084–5.
Bradley KJ, Wass JA, Turner HE. Non-functioning pituitary adenomas with positive immunoreactivity for ACTH behave more aggressively than ACTH immunonegative tumours but do not recur more frequently. Clin Endocrinol (Oxf) 2003, 58: 59–64.
Ekramullah SM, Saitoh Y, Arita N, Ohnishi T, Hayakawa T. The correlation of Ki-67 staining indices with tumour doubling times in regrowing non-functioning pituitary adenomas. Acta Neurochir (Wien) 1996, 138: 1449–55.
Tanaka Y, Hongo K, Tada T, Sakai K, Kakizawa Y, Kobayashi S. Growth pattern and rate in residual nonfunctioning pituitary adenomas: correlations among tumor volume doubling time, patient age, and MIB-1 index. J Neurosurg 2003, 98: 359–65.
Losa M, Franzin A, Mangili F, et al. Proliferation index of nonfunctioning pituitary adenomas: correlations with clinical characteristics and long term follow up results. Neurosurgery 2000, 47: 1313–8; discussion 1318–9.
Dubois S, Guyétant S, Menei P, et al. Relevance of Ki-67 and prognostic factors for recurrence/progression of gonadotropic adenomas after first surgery. Eur J Endocrinol 2007, 157: 141–7.
Brada M, Rajan B, Traish D, et al. The long-term efficacy of conservative surgery and radiotherapy in the control of pituitary adenomas. Clin Endocrinol (Oxf) 1993, 38: 571–8.
Hughes MN, Llamas KJ, Yelland ME, Obst D, Tripcony LB. Pituitary adenomas: long-term results for radiotherapy alone and post-operative radiotherapy. Int J Radiat Oncol Biol Phys 1993, 27: 1035–43.
Tsang RW, Brierley JD, Panzarella T, Gospodarowicz MK, Sutcliffe SB, Simpson WJ. Radiation therapy for pituitary adenoma: treatment outcome and prognostic factors. Int J Radiat Oncol Biol Phys 1994, 15: 557–65.
Breen P, Flickinger JC, Kondziolka D, Martinez AJ. Radiotherapy for nonfunctional pituitary adenoma: analysis of long-term tumor control. J Neurosurg 1998, 89: 933–8.
Paek SH, Downes MB, Bednarz G, et al. Integration of surgery with fractionated stereotactic radiotherapy for treatment of nonfunctioning pituitary macroadenomas. Int J Radiat Oncol Biol Phys 2005, 61: 795–808.
Minniti G, Jaffrain-Rea ML, Osti M, Cantore G, Enrici RM. Radiotherapy for nonfunctioning pituitary adenomas: from conventional to modern stereotactic radiation techniques. Neurosurg Rev 2007, 30: 167–76.
Kanner AA, Corn BW, Greenman Y. Radiotherapy of nonfunctioning and gonadotroph adenomas. Pituitary 2009, 12: 15–22.
Schalin-Jantti C, Valanne L, Tenhunen M, et al. Outcome of fractionated stereotactic radiotherapy in patients with pituitary adenomas resistant to conventional treatments: a 5.25-year follow-up study. Clin Endocrinol (Oxf) 2010, 73: 72–7.
Flickinger JC, Nelson PB, Martinez AJ, Deutsch M, Taylor F. Radiotherapy of nonfunctional adenomas of the pituitary gland. Results with long-term follow-up. Cancer 1989, 63: 2409–14.
Wowra B, Stummer W. Efficacy of gamma knife radiosurgery for nonfunctioning pituitary adenomas: a quantitative follow-up with magnetic resonance imaging-based volumetric analysis. J Neurosurg 2002, 97 (5 Suppl): 429–32.
Petrovich Z, Yu C, Giannotta SL, Zee CS, Apuzzo ML. Gamma knife for pituitary adenoma: early results. Neurosurgery 2003, 53: 51–9; discussion 59–61.
Losa M, Valle M, Mortini P, et al. Gamma knife surgery for treatment of residual nonfunctioning pituitary adenomas after surgical debulking. J Neurosurg 2004, 100: 438–44.
Iwai Y, Yamanaka K, Yoshioka K. Radiosurgery for nonfunctioning pituitary adenomas. Neurosurgery 2005, 56: 699–705.
Liscák R, Vladyka V, Marek J, Simonová G, Vymazal J. Gamma knife radiosurgery for endocrine-inactive pituitary adenomas. Acta Neurochir(Wien) 2007, 149: 999–1006; discussion 1006.
Pollock BE, Cochran J, Natt N, et al. Gamma knife radiosurgery for patients with nonfunctioning pituitary adenomas: results from a 15-year experience. Int J Radiat Oncol Biol Phys 2008, 70: 1325–9.
Feigl GC, Bonelli CM, Berghold A, Mokry M. Effects of gamma knife radiosurgery of pituitary adenomas on pituitary function. J Neurosurg 2002, 97 (5 Suppl): 415–21.
Mingione V, Yen CP, Vance ML, et al. Gamma surgery in the treatment of nonsecretory pituitary macroadenoma. J Neurosurg 2006, 104: 876–83.
Kobayashi T. Long-term results of stereotactic gamma knife radiosurgery for pituitary adenomas. Specific strategies for different types of adenoma. Prog Neurol Surg 2009, 22: 77–95.
Höybye C, Rähn T. Adjuvant Gamma Knife radiosurgery in nonfunctioning pituitary adenomas; low risk of long-term complications in selected patients. Pituitary 2009, 12: 211–6.
Picozzi P, Losa M, Mortini P, et al. Radiosurgery and the prevention of regrowth of incompletely removed nonfunctioning pituitary adenomas. J Neurosurg 2005, 102 (Suppl): 71–4.
Kajiwara K, Saito K, Yoshikawa K, et al. Image-guided stereotactic radiosurgery with the CyberKnife for pituitary adenomas. Minim Invasive Neurosurg 2005, 48: 91–6.
Killory BD, Kresl JJ, Wait SD, Ponce FA, Porter R, White WL. Hypofractionated CyberKnife radiosurgery for perichiasmatic pituitary adenomas: early results. Neurosurgery 2009, 64 (Suppl): A19–25.
Minniti G, Traish D, Ashley S, Gonsalves A, Brada M. Risk of second brain tumor after conservative surgery and radiotherapy for pituitary adenoma: update after an additional 10 years. J Clin Endocrinol Metab 2005, 90: 800–4.
Tsang RW, Laperriere NJ, Simpson WJ, Brierley J, Panzarella T, Smyth HS. Glioma arising after radiation therapy for pituitary adenoma. A report of four patients and estimation of risk. Cancer 1993, 72: 2227–33. Erratum in: Cancer 1994, 73: 492.
Erfurth EM, Bülow B, Mikoczy Z, Svahn-Tapper G, Hagmar L. Is there an increase in second brain tumours after surgery and irradiation fora pituitary tumour? Clin Endocrinol (Oxf) 2001, 55: 613–6.
Brada M, Burchell L, Ashley S, Traish D. The incidence of cerebrovascular accidents in patients with pituitary adenoma. Int J Radiat Oncol Biol Phys 1999, 45: 693–8.
Erfurth EM, Bülow B, Svahn-Tapper G, et al. Risk factors for cerebrovascular deaths in patients operated and irradiated for pituitary tumors. J Clin Endocrinol Metab 2002, 87: 4892–9.
Page RC, Hammersley MS, Burke CW, Wass JH. An account of the quality of life of patients after treatment for non-functioning pituitary tumours. Clin Endocrinol (Oxf) 1997, 46: 401–6.
Van Beek AP, van den Bergh AC, van den Berg LM, et al. Radiotherapy is not associated with reduced quality of life and cognitive function in patients treated for nonfunctioning pituitary adenoma. Int J Radiat Oncol Biol Phys, 2007, 68: 986–91.
Minniti G, Traish D, Ashley S, Gonsalves A, Brada M. Fractionated stereotactic conformal radiotherapy for secreting and nonsecreting pituitary adenomas. Clin Endocrinol (Oxf) 2006, 64: 542–8.
Rowe J, Grainger A, Walton L, Silcocks P, Radatz M, Kemeny A. Risk of malignancy after gamma knife stereotactic radiosurgery. Neurosurgery 2007, 60: 60–5; discussion 65–6.
Höybye C, Grenbäck E, Rähn T, Degerblad M, Thorén M, Hulting AL. Adrenocorticotropic hormone-producing pituitary tumors: 12-to 22-year follow-up after treatment with stereotactic radiosurgery. Neurosurgery 2001, 49: 284–91; discussion 291–2.
Cozzi R, Lasio G, Cardia A, Felisati G, Montini M, Attanasio R. Perioperative cortisol can predict hypothalamus-pituitary-adrenal status in clinically non-functioning pituitary adenomas. J Endocrinol Invest 2009, 32: 460–4.